Massachusetts Board of Registration in Medicine advertising rules — the marketing compliance guide

Which boards actually regulate Massachusetts advertising

Massachusetts sits under the Division of Occupational Licensure, and physician advertising is regulated by the Board of Registration in Medicine under authority delegated by M.G.L. Chapter 112. Physician assistants fall under the same board. Osteopathic physicians licensed as MDs in Massachusetts also sit under the BORM — Massachusetts is one of the states that does not maintain a separate osteopathic board, which simplifies advertising review compared to states like Arizona or Michigan.

The Massachusetts Board of Registration in Dentistry handles dental advertising under substantively parallel rules. Chiropractic, optometry, nursing and other licensed healthcare disciplines each have their own boards, but the same core prohibition — false, deceptive or misleading advertising — appears across every one of them. The pattern-of-practice standard the Massachusetts Attorney General applies under Chapter 93A is the third layer that sits over every board and creates the parallel civil-exposure track.

The Chapter 93A consumer-protection framework is what makes Massachusetts materially different from most states. Chapter 93A creates a private right of action for unfair or deceptive acts or practices in trade or commerce. A prevailing plaintiff may recover double or treble damages plus attorneys fees. Healthcare advertising is squarely within the scope of the statute. That means a Massachusetts advertising claim can be litigated by a private plaintiff — a competitor, a former patient, a class of consumers — under Chapter 93A, entirely independent of the BORM's own action or timing. The Attorney General's Office may also bring its own action under Chapter 93A Section 4.

The federal baseline still applies. HIPAA on the privacy side. TCPA on outbound telephony and SMS. CAN-SPAM on commercial email. FTC Act and FTC Endorsement Guides on truthful advertising and testimonials. ADA and Section 508 on website accessibility. FDA off-label promotion rules on pharmaceutical and device advertising. A Massachusetts pre-publication review that clears the state ceiling still needs to clear each of the federal floor requirements.

Chapter 93A consumer-protection overlay

Chapter 93A is what makes the Massachusetts advertising risk profile different from every other state. Understanding how it works alongside the BORM rules is central to the risk conversation with any Massachusetts practice-owner.

Section 2 — the substantive prohibition

Section 2 declares unfair methods of competition and unfair or deceptive acts or practices in trade or commerce unlawful. Healthcare advertising is squarely within the scope of the statute. A BORM advertising finding will typically also be a Chapter 93A violation, because both statutes reach the same conduct through different frames.

Section 9 — private right of action for consumers

Section 9 gives an individual consumer a private right of action, subject to a pre-suit demand letter under Section 9(3). If a plaintiff prevails and the defendant's conduct is found to be a "willful or knowing" violation, or the defendant's response to the demand letter was in bad faith, the court may award double or treble damages plus attorneys fees. The doubling or trebling and the attorneys-fee shift make Chapter 93A a materially different litigation calculus from a standard consumer-protection statute.

Section 11 — private right of action between businesses

Section 11 gives a business a right of action against another business for unfair or deceptive practices. Competitor-versus-competitor Chapter 93A actions are common in the Massachusetts healthcare-advertising space, particularly among competing aesthetic brands.

Section 4 — Attorney General action

Section 4 authorises the Massachusetts Attorney General to bring an action for injunctive and other equitable relief when it appears that a person is engaging in an unfair or deceptive practice.

The practical consequence for a Massachusetts marketing programme is that every campaign is reviewed simultaneously against two overlapping standards — 243 CMR 2.07 for the board risk, Chapter 93A for the civil-litigation risk — and that the disclosure and substantiation standards required by the second are, in most cases, stricter than what would clear the first.

Common Massachusetts violation patterns

Complaint volume in Massachusetts clusters into a recognisable pattern shaped by the Boston-Cambridge academic-medicine environment and the aggressive Chapter 93A private-plaintiff bar.

• Academic-affiliation drift. "Harvard-trained", "MGH-affiliated", "Beth Israel Deaconess" claims that overstate the currency or scope of the affiliation. Historical training must be date-limited; current affiliation must accurately describe the arrangement.
• Superlative language without substantiation. "Boston's best", "leading", "top-ranked", "most experienced". Common in market and consistently draws Chapter 93A demand letters even where BORM has not yet acted.
• Undisclosed medspa medical direction. Non-physician-owned medspa brands that do not identify the supervising physician on the ad or the immediately linked landing page.
• Non-ABMS certification framed as specialty. A membership society described as if it were an ABMS-recognised specialty. Correction is a qualifying disclosure or removal of specialty language.
• Guaranteed outcome language. "Guaranteed results", "money-back if not satisfied" tied to clinical outcome rather than service quality.
• Undisclosed material connection on endorsement. Instagram and TikTok influencer content that appears organic but is actually compensated, without an FTC-compliant disclosure.
• Stale credential and affiliation pages. Directory pages continuing to display credentials, hospital affiliations or academic appointments that have lapsed or changed. Monthly credential reconciliation is the practical control.
• Pricing offers without full material-fact disclosure. Advertised prices that require unadvertised purchases to obtain, promotions without expiry, offers without eligibility conditions.

Every pattern on the list is curable at the pre-publication review stage. The Chapter 93A overlay means that curing it later — after publication, after a demand letter — is substantially more expensive than curing it before publication.

Boston academic-medicine advertising specifics

The concentration of academic medical centres, teaching hospitals and university-affiliated practices in Boston and Cambridge creates a distinctive advertising environment. Board attention concentrates on affiliation accuracy, specialty designation, and comparative-outcome claims.

Academic affiliation language

"Harvard-trained", "MGH-affiliated", "Brigham-associated" — the language is common in market and legitimate when accurate. The two failure modes are staleness (physician no longer holds the appointment) and scope-drift (a training relationship described as a current appointment, or an observership described as a fellowship). Massachusetts advertising review should verify current appointment status through the institution's own directory and date-limit any historical training language.

Comparative outcome claims

Academic-affiliated practices often want to reference procedure volume, publication record, or outcome data. Every such claim requires a dated substantiation row referencing the underlying source — a peer-reviewed publication, an institution-maintained registry, a public quality reporting dataset. Comparisons to unnamed competitors ("higher success rate than the alternative") are difficult to substantiate and typically create Chapter 93A exposure disproportionate to the campaign benefit.

Research and clinical-trial promotion

Advertising for clinical trials sits under a parallel IRB-approval regime. IRB-approved recruitment language must be used verbatim, and marketing amplification of the recruitment must not alter the risk-benefit framing the IRB approved.